Home > > > Paroxysmal Nocturnal Hemoglobinuria Market Poised for Strong Expansion (2025–2034)

Paroxysmal Nocturnal Hemoglobinuria Market Poised for Strong Expansion (2025–2034)

Author : John snow | Published On : 17 Mar 2026

The paroxysmal nocturnal hemoglobinuria (PNH) market is experiencing significant growth, fueled by heightened awareness, advanced diagnostics, and the increasing adoption of precision therapies. Complement inhibitors such as Eculizumab and Ravulizumab have revolutionized PNH management. Promising pipeline assets such as Pozelimab + Cemdisiran, Zaltenibart, Ruxoprubart, and others are expected to accelerate further market momentum.

New York, USA, July 01, 2025 (GLOBE NEWSWIRE) -- The paroxysmal nocturnal hemoglobinuria market is witnessing robust growth during the forecast period 2025–2034, driven by increasing disease awareness, improved diagnostic technologies, and expanding use of targeted therapies. The approval and growing adoption of complement inhibitors such as Eculizumab and Ravulizumab have significantly transformed the treatment landscape. Emerging pipeline candidates, including Pozelimab + Cemdisiran, Zaltenibart, and Ruxoprubart, are expected to further drive market expansion.

DelveInsight’s Paroxysmal Nocturnal Hemoglobinuria Market Insights report provides comprehensive analysis of current treatment practices, emerging PNH therapies, therapy market shares, and market size projections from 2020 to 2034 across the 7MM — the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Paroxysmal Nocturnal Hemoglobinuria Market Report

  • DelveInsight estimates the 7MM PNH market at USD 1.3 billion in 2024.
     

  • The United States dominates the market, accounting for approximately 85% share, compared with the EU4, UK, and Japan.
     

  • Around 16,000 diagnosed prevalent PNH cases were reported in the 7MM in 2024, and this number is expected to increase by 2034.
     

  • Leading developers such as Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation, and NovelMed Therapeutics are advancing innovative therapies for PNH.
     

  • Key pipeline candidates—including Pozelimab + Cemdisiran, Zaltenibart, and Ruxoprubart—are expected to significantly reshape the treatment landscape.
     

Discover which paroxysmal nocturnal hemoglobinuria medications are expected to grab the market share @ Paroxysmal Nocturnal Hemoglobinuria Market Report

Paroxysmal Nocturnal Hemoglobinuria Overview

Paroxysmal nocturnal hemoglobinuria is a rare acquired hematologic disorder caused by somatic mutations in the PIG-A gene within hematopoietic stem cells, leading to impaired synthesis of glycosylphosphatidylinositol (GPI) anchors. This defect results in deficiency of complement regulatory proteins CD55 (DAF) and CD59 (MIRL) on blood cells, causing complement-mediated hemolysis, hemoglobinuria, thrombosis, and cytopenias.

Modern diagnostic approaches rely on flow cytometry using FLAER or anti-CD55/CD59 antibodies, which have largely replaced older diagnostic methods such as the Ham test and sucrose hemolysis test.

Paroxysmal Nocturnal Hemoglobinuria Epidemiology Segmentation

DelveInsight’s epidemiology analysis evaluates trends from 2020 to 2034 across the 7MM, including:

  • Total Diagnosed Prevalent Cases
     

  • Gender-Specific Cases
     

  • Age-Specific Cases
     

  • Treated Cases
     

Download the report to understand which factors are driving paroxysmal nocturnal hemoglobinuria epidemiology trends @ Paroxysmal Nocturnal Hemoglobinuria Treatment Algorithm

Paroxysmal Nocturnal Hemoglobinuria Treatment Market

Complement C5 inhibitors such as Eculizumab and Ravulizumab remain the cornerstone of therapy, with ravulizumab offering extended dosing intervals and improved patient convenience. Newer therapeutic options include the C3 inhibitor Pegcetacoplan and the oral Factor B inhibitor Iptacopan, expanding treatment strategies by targeting proximal complement pathways.

Learn more about the paroxysmal nocturnal hemoglobinuria treatment options @ Paroxysmal Nocturnal Hemoglobinuria Treatment Guidelines

Paroxysmal Nocturnal Hemoglobinuria Emerging Drugs and Companies

The PNH pipeline continues to gain momentum with innovative therapies being developed by companies such as Regeneron Pharmaceuticals, Omeros Corporation, and NovelMed Therapeutics.

  • Pozelimab – a Phase III C5 inhibitor developed using Regeneron’s VelocImmune technology.
     

  • Zaltenibart (OMS906) – a Phase II MASP-3 inhibitor with Orphan Drug designation.
     

  • Ruxoprubart (NM8074) – a Phase II anti-Bb monoclonal antibody with Orphan Drug status for PNH.
     

These emerging therapies have the potential to redefine treatment paradigms and expand therapeutic options for patients with PNH.

To know more about new treatment for paroxysmal nocturnal hemoglobinuria, visit @ Paroxysmal Nocturnal Hemoglobinuria Management

Paroxysmal Nocturnal Hemoglobinuria Market Dynamics

The PNH market is being propelled by deeper insights into complement biology, the pioneering success of the first C5 inhibitor Eculizumab, the entry of biosimilars such as Bkemv and Epysqli, and improved treatment accessibility. However, challenges remain, including persistent residual hemolysis in some patients, limited disease awareness in certain regions, pricing pressures on biologic therapies, and a significant number of undiagnosed cases worldwide.

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

 

Paroxysmal Nocturnal Hemoglobinuria - Epidemiology Forecast - 2034

DelveInsight’s “Paroxysmal nocturnal hemoglobinuria (PNH)” report delivers an in-depth understanding of Paroxysmal nocturnal hemoglobinuria (PNH), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Paroxysmal Nocturnal Hemoglobinuria Companies developing potential therapies include - Hoffmann-La Roche, Alexion Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, and others.

 

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2026

DelveInsight’s, “Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2026,” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. The leading Paroxysmal Nocturnal Hemoglobinuria Companies developing potential therapies include - Hoffmann-La Roche, Alexion Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: [email protected]

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com